Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Perflutren

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lantheus Announces the Approval of DEFINITY by China’s NMPA
    Lantheus Announces the Approval of DEFINITY by China’s NMPA

    28 Nov 2022

    // PRESS RELEASE

    https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-announces-approval-definityr-perflutren-lipid

    PRESS RELEASE
    28 Nov 2022
    Share Share
    FDA Approves GE Healthcare for Contraindications in PI for Optison
    FDA Approves GE Healthcare for Contraindications in PI for Optison

    05 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211005005646/en

    BUSINESSWIRE
    05 Oct 2021
    Share Share
    Health Canada Issues Class II Drug Recall of Alburex-25 Solution
    Health Canada Issues Class II Drug Recall of Alburex-25 Solution

    11 Feb 2019

    // HEALTH CANADA

    https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69014r-eng.php

    HEALTH CANADA
    11 Feb 2019
    Share Share